Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma

被引：0
|
作者：
Hanwool Jeon
Joonho Byun
Hayeong Kang
Kyunggon Kim
Eunyeup Lee
Jeong Hoon Kim
Chang Ki Hong
Sang Woo Song
Young-Hoon Kim
Sangjoon Chong
Jae Hyun Kim
Soo Jeong Nam
Ji Eun Park
Seungjoo Lee
机构：
[1] Asan Medical Center,Translational Biomedical Research Group, Asan Institute for Life Sciences
[2] University of Ulsan College of Medicine 88,Department of Neurological Surgery, Brain Tumor Center, Asan Medical Center
[3] Asan Medical Center,Asan Institute for Life Sciences
[4] University of Ulsan College of Medicine,Department of Pathology, Asan Medical Center
[5] University of Ulsan College of Medicine,Department of Radiology and Research Institute of Radiology, Asan Medical Center
[6] University of Ulsan College of Medicine,Bio
来源：
Journal of Translational Medicine | / 21卷
关键词：
Anti-angiogenic resistance; Prediction biomarker; Proteomics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Autophagy as a mechanism for anti-angiogenic therapy resistance
    Chandra, Ankush
    Rick, Jonathan
    Yagnik, Garima
    Aghi, Manish K.
    SEMINARS IN CANCER BIOLOGY, 2020, 66 : 75 - 88
  • [32] Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma
    Ahmad Joshkon
    Emeline Tabouret
    Wael Traboulsi
    Richard Bachelier
    Stéphanie Simoncini
    Sandrine Roffino
    Carine Jiguet-Jiglaire
    Bassam Badran
    Benjamin Guillet
    Alexandrine Foucault-Bertaud
    Aurelie S. Leroyer
    Françoise Dignat-George
    Olivier Chinot
    Hussein Fayyad-Kazan
    Nathalie Bardin
    Marcel Blot-Chabaud
    Acta Neuropathologica Communications, 10
  • [33] Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma
    Joshkon, Ahmad
    Tabouret, Emeline
    Traboulsi, Wael
    Bachelier, Richard
    Simoncini, Stephanie
    Roffino, Sandrine
    Jiguet-Jiglaire, Carine
    Badran, Bassam
    Guillet, Benjamin
    Foucault-Bertaud, Alexandrine
    Leroyer, Aurelie S.
    Dignat-George, Francoise
    Chinot, Olivier
    Fayyad-Kazan, Hussein
    Bardin, Nathalie
    Blot-Chabaud, Marcel
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2022, 10 (01)
  • [34] Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma
    Zhang, Ashley B. B.
    Mozaffari, Khashayar
    Aguirre, Brian
    Li, Victor
    Kubba, Rohan
    Desai, Nilay C.
    Wei, Darren
    Yang, Isaac
    Wadehra, Madhuri
    CANCERS, 2023, 15 (03)
  • [35] Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
    Verhoeff, Joost J. C.
    van Tellingen, Olaf
    Claes, An
    Stalpers, Lukas J. A.
    van Linde, Myra E.
    Richel, Dirk J.
    Leenders, William P. J.
    van Furth, Wouter R.
    BMC CANCER, 2009, 9
  • [36] Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme
    Onishi, Manabu
    Kurozumi, Kazuhiko
    Ichikawa, Tomotsugu
    Date, Isao
    NEUROLOGIA MEDICO-CHIRURGICA, 2013, 53 (11) : 755 - 763
  • [37] Identification of the hidden survival advantage for anti-angiogenic therapy in glioblastoma
    Nabors, Burt
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (01) : 72 - 74
  • [38] A is for anti-angiogenic
    不详
    NATURE MEDICINE, 2001, 7 (04) : 418 - 418
  • [39] Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma
    Dietrich, Joerg
    Wang, Daphne
    Batchelor, Tracy T.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (10) : 1549 - 1557
  • [40] Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
    Joost JC Verhoeff
    Olaf van Tellingen
    An Claes
    Lukas JA Stalpers
    Myra E van Linde
    Dirk J Richel
    William PJ Leenders
    Wouter R van Furth
    BMC Cancer, 9
12345